TTM
$33.14B
YoY change
+69.7%
5Y CAGR
+32.7%
Peak year (2025)
$29.70B
Cumulative operating income
$207.60B
Operating Income history chart for Eli Lilly (LLY) from 1985 to 2025
Latest: $29.70B
Operating Income growth chart for Eli Lilly (LLY) from 1985 to 2025
Latest: +69.7%
Operating Income history table for Eli Lilly (LLY) from 1985 to 2025
| 2025 | $29.70B | +69.7% | +$12.19B | ||
| 2024 | $17.50B | +62.2% | +$6.71B | ||
| 2023 | $10.79B | +24.7% | +$2.13B | ||
| 2022 | $8.65B | +9.1% | +$720.30M | ||
| 2021 | $7.93B | +10.0% | +$722.20M | ||
| 2020 | $7.21B | +20.2% | +$1.21B | ||
| 2019 | $6.00B | -0.4% | −$26.40M | ||
| 2018 | $6.03B | +41.8% | +$1.78B | ||
| 2017 | $4.25B | +9.8% | +$378.50M | ||
| 2016 | $3.87B | +7.8% | +$279.20M | ||
| 2015 | $3.59B | +7.9% | +$263.40M | ||
| 2014 | $3.33B | -40.0% | −$2.22B | ||
| 2013 | $5.55B | +10.6% | +$532.80M | ||
| 2012 | $5.02B | -20.6% | −$1.30B | ||
| 2011 | $6.32B | -6.7% | −$454.30M | ||
| 2010 | $6.77B | +6.3% | +$402.20M | ||
| 2009 | $6.37B | +15.2% | +$842.10M | ||
| 2008 | $5.53B | +15.1% | +$725.00M | ||
| 2007 | $4.80B | +16.4% | +$677.50M | ||
| 2006 | $4.13B | +13.1% | +$476.80M | ||
| 2005 | $3.65B | -0.3% | −$10.10M | ||
| 2004 | $3.66B | +4.5% | +$156.90M | ||
| 2003 | $3.50B | +5.2% | +$174.10M | ||
| 2002 | $3.33B | -10.8% | −$402.10M | ||
| 2001 | $3.73B | +4.8% | +$170.10M | ||
| 2000 | $3.56B | +5.8% | +$196.00M | ||
| 1999 | $3.36B | +19.1% | +$539.20M | ||
| 1998 | $2.82B | +15.8% | +$386.10M | ||
| 1997 | $2.44B | +19.3% | +$394.10M | ||
| 1996 | $2.04B | +3.2% | +$62.50M | ||
| 1995 | $1.98B | +10.4% | +$186.90M | ||
| 1994 | $1.79B | +175.0% | +$1.14B | ||
| 1993 | $652.60M | -43.5% | −$502.90M | ||
| 1992 | $1.16B | -34.7% | −$612.80M | ||
| 1991 | $1.77B | +14.9% | +$228.90M | ||
| 1990 | $1.54B | +32.2% | +$374.60M | ||
| 1989 | $1.16B | +11.3% | +$118.00M | ||
| 1988 | $1.05B | +75.9% | +$451.80M | ||
| 1987 | $595.00M | -30.8% | −$265.30M | ||
| 1986 | $860.30M | +12.5% | +$95.90M | ||
| 1985 | $764.40M | — | — |
- 2025$29.70B+69.7%
- 2024$17.50B+62.2%
- 2023$10.79B+24.7%
- 2022$8.65B+9.1%
- 2021$7.93B+10.0%
- 2020$7.21B+20.2%
- 2019$6.00B-0.4%
- 2018$6.03B+41.8%
- 2017$4.25B+9.8%
- 2016$3.87B+7.8%
- 2015$3.59B+7.9%
- 2014$3.33B-40.0%
- 2013$5.55B+10.6%
- 2012$5.02B-20.6%
- 2011$6.32B-6.7%
- 2010$6.77B+6.3%
- 2009$6.37B+15.2%
- 2008$5.53B+15.1%
- 2007$4.80B+16.4%
- 2006$4.13B+13.1%
- 2005$3.65B-0.3%
- 2004$3.66B+4.5%
- 2003$3.50B+5.2%
- 2002$3.33B-10.8%
- 2001$3.73B+4.8%
- 2000$3.56B+5.8%
- 1999$3.36B+19.1%
- 1998$2.82B+15.8%
- 1997$2.44B+19.3%
- 1996$2.04B+3.2%
- 1995$1.98B+10.4%
- 1994$1.79B+175.0%
- 1993$652.60M-43.5%
- 1992$1.16B-34.7%
- 1991$1.77B+14.9%
- 1990$1.54B+32.2%
- 1989$1.16B+11.3%
- 1988$1.05B+75.9%
- 1987$595.00M-30.8%
- 1986$860.30M+12.5%
- 1985$764.40M—
Operating Income values are taken from Eli Lilly's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Income at Eli Lilly (LLY)
According to Eli Lilly's latest reported financial statements, the company's current operating income (TTM) is $33.14B. Operating income is profit from core operations: revenue minus cost of goods sold and operating expenses (SG&A, R&D). It excludes interest, taxes, and non-operating items, so it isolates how profitable the business itself is before financing and tax decisions. Compare with EBITDA and net income.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
2025's annual operating income for Eli Lilly (LLY) came in at $29.70B – surged 69.7% year-over-year.
Through 2020–2025 (5 years), Eli Lilly operating income delivered a +32.7% annualised rate; sustaining 6 straight years of year-over-year growth.
2025 marks the peak operating income at $29.70B, with the historical low of $595.00M recorded in 1987.
Eli Lilly Operating Income by Year
Eli Lilly Operating Income 2025: $29.70B
Eli Lilly operating income in 2025 was $29.70B, surged 69.7% from 2024. This figure represents the highest annual value in the available history.
Eli Lilly Operating Income 2024: $17.50B
2024's operating income for Eli Lilly came in at $17.50B, surged 62.2% from 2023.
Eli Lilly Operating Income 2023: $10.79B
Eli Lilly posted operating income of $10.79B in 2023, grew 24.7% from 2022.
Eli Lilly Operating Income 2022: $8.65B
In 2022, Eli Lilly reported operating income of $8.65B, grew 9.1% from 2021.
Eli Lilly Operating Income 2021: $7.93B
Eli Lilly operating income in 2021 was $7.93B.
See more financial history for Eli Lilly (LLY).
Sector peers by Operating Income
Healthcare peers of Eli Lilly (LLY), ranked by their latest operating income
| $25.60B | |
| $23.49B | |
| $20.09B | |
| $19.90B | |
| $18.96B | |
| $13.74B | |
| $10.68B | |
| $8.11B |
- $25.60B
- $23.49B
- $20.09B
- $19.90B
- $18.96B
- $13.74B
- $10.68B
Frequently asked questions
Eli Lilly (LLY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation